Electrical Stimulation for Vision Neuroenhancement in Glaucoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
The purpose of the study is to evaluate the efficacy, transorbital alternating current stimulation (rtACS) using the EYETRONIC for the treatment in patients with glaucoma.
Eligibility criteria
Qualifiers
Participant must be at least 18.
Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).
Participant's clinical diagnosis must be consistent with primary open angle glaucoma (including but not limited to normal tension, low tension or general open angle) characterized by the following features: Mean deviation (MD) worse than -6 but better than -20 on reliable Humphrey Visual Field 24-2 testing
Participant's eye pressure must be clinically stable, with IOP < 18.
Disqualifiers
Participant is unable to comply with study procedures or follow-up visits.
Participant has a history of ocular herpes zoster.
Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study.
Participant has evidence of corneal opacification or lack of optical clarity.
Trial design
Treatments tested in this trial
- Eyetronic rtACS
- Sham rtACS
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Stanford University
Lead sponsor
EYETRONIC, Inc
Collaborator
Source ClinicalTrials.gov